Source comparison
Comparison Table: KPV Dosing by IBD Severity and Inflammatory Load
The following table maps starting KPV doses to baseline disease severity, inflammatory markers, and expected escalation timelines. Mild UC or Crohn's (localized inflammation, no systemic symptoms) 150–300 <5 500 mcg daily Increase to 750 mcg at week 3 if calpr
This comparison does not assign a generated winner or score.
- The following table maps starting KPV doses to baseline disease severity, inflammatory markers, and expected escalation timelines.
- Mild UC or Crohn's (localized inflammation, no systemic symptoms)
- 150–300
- <5
- 500 mcg daily
- Increase to 750 mcg at week 3 if calprotectin >150
- 750–1000 mcg daily
- Conservative dosing appropriate. Escalate only if biomarkers plateau above remission thresholds
- Moderate IBD (diffuse mucosal inflammation, systemic symptoms present)
- 300–600
- 5–15
- 1000 mcg daily
- Increase to 1500 mcg at week 3 if CRP remains >5 or calprotectin >250
- 1500 mcg daily
- Mid-range dosing targets mucosal healing within 8–12 weeks. Monitor endoscopic findings
- Severe IBD (extensive ulceration, anemia, weight loss, hypoalbuminemia)
- >600
- >15
- Increase to 2000 mcg at week 2 if no CRP drop or persistent bloody stools
- 2000 mcg daily
- Aggressive dosing required. KPV adjunct to biologics, not monotherapy. Reassess at 6 weeks
- Microscopic colitis (normal endoscopy, histologic inflammation only)
- <150 (often normal)
- <3
- Hold at 500 mcg unless diarrhea persists beyond week 4
- 500–750 mcg daily
- Lower doses sufficient for non-ulcerative inflammatory patterns. Symptom resolution primary endpoint